vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and FTAI Infrastructure Inc. (FIP). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $143.5M, roughly 1.7× FTAI Infrastructure Inc.). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -68.1%, a 79.2% gap on every dollar of revenue. On growth, FTAI Infrastructure Inc. posted the faster year-over-year revenue change (77.7% vs 29.6%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-68.6M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 31.9%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
FTAI Infrastructure Inc. owns, operates and invests in high-quality critical infrastructure assets across core sectors including transportation logistics, midstream energy, and power generation. It primarily serves North American markets, focusing on assets with stable long-term cash flows, contracted revenue streams, and strong market positions to deliver sustainable returns for stakeholders.
ANIP vs FIP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $143.5M |
| Net Profit | $27.5M | $-97.7M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | -45.7% |
| Net Margin | 11.1% | -68.1% |
| Revenue YoY | 29.6% | 77.7% |
| Net Profit YoY | 367.5% | 21.6% |
| EPS (diluted) | $1.14 | $-1.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $143.5M | ||
| Q3 25 | $227.8M | $140.6M | ||
| Q2 25 | $211.4M | $122.3M | ||
| Q1 25 | $197.1M | $96.2M | ||
| Q4 24 | $190.6M | $80.8M | ||
| Q3 24 | $148.3M | $83.3M | ||
| Q2 24 | $138.0M | $84.9M | ||
| Q1 24 | $137.4M | $82.5M |
| Q4 25 | $27.5M | $-97.7M | ||
| Q3 25 | $26.6M | $-104.5M | ||
| Q2 25 | $8.5M | $-70.0M | ||
| Q1 25 | $15.7M | $120.2M | ||
| Q4 24 | $-10.3M | $-124.7M | ||
| Q3 24 | $-24.2M | $-43.0M | ||
| Q2 24 | $-2.3M | $-48.1M | ||
| Q1 24 | $18.2M | $-50.3M |
| Q4 25 | 14.1% | -45.7% | ||
| Q3 25 | 15.9% | -70.8% | ||
| Q2 25 | 6.6% | -56.4% | ||
| Q1 25 | 13.3% | 81.8% | ||
| Q4 24 | -2.3% | -152.7% | ||
| Q3 24 | -13.8% | -51.7% | ||
| Q2 24 | 3.7% | -56.4% | ||
| Q1 24 | 14.8% | -58.8% |
| Q4 25 | 11.1% | -68.1% | ||
| Q3 25 | 11.7% | -74.4% | ||
| Q2 25 | 4.0% | -57.2% | ||
| Q1 25 | 8.0% | 125.0% | ||
| Q4 24 | -5.4% | -154.4% | ||
| Q3 24 | -16.3% | -51.6% | ||
| Q2 24 | -1.7% | -56.7% | ||
| Q1 24 | 13.2% | -60.9% |
| Q4 25 | $1.14 | $-1.04 | ||
| Q3 25 | $1.13 | $-1.38 | ||
| Q2 25 | $0.36 | $-0.73 | ||
| Q1 25 | $0.69 | $0.89 | ||
| Q4 24 | $-0.45 | $-1.21 | ||
| Q3 24 | $-1.27 | $-0.45 | ||
| Q2 24 | $-0.14 | $-0.52 | ||
| Q1 24 | $0.82 | $-0.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $57.4M |
| Total DebtLower is stronger | — | $3.8B |
| Stockholders' EquityBook value | $540.7M | $21.3M |
| Total Assets | $1.4B | $5.7B |
| Debt / EquityLower = less leverage | — | 176.99× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $57.4M | ||
| Q3 25 | $262.6M | $34.7M | ||
| Q2 25 | $217.8M | $33.6M | ||
| Q1 25 | $149.8M | $26.3M | ||
| Q4 24 | $144.9M | $27.8M | ||
| Q3 24 | $145.0M | $20.3M | ||
| Q2 24 | $240.1M | $33.1M | ||
| Q1 24 | $228.6M | $23.0M |
| Q4 25 | — | $3.8B | ||
| Q3 25 | — | $3.7B | ||
| Q2 25 | — | $3.1B | ||
| Q1 25 | — | $2.8B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.6B | ||
| Q1 24 | — | $1.3B |
| Q4 25 | $540.7M | $21.3M | ||
| Q3 25 | $505.8M | $181.1M | ||
| Q2 25 | $436.8M | $375.5M | ||
| Q1 25 | $418.6M | $476.2M | ||
| Q4 24 | $403.7M | $202.7M | ||
| Q3 24 | $405.9M | $370.8M | ||
| Q2 24 | $455.8M | $394.8M | ||
| Q1 24 | $452.0M | $402.5M |
| Q4 25 | $1.4B | $5.7B | ||
| Q3 25 | $1.4B | $5.5B | ||
| Q2 25 | $1.3B | $4.4B | ||
| Q1 25 | $1.3B | $4.1B | ||
| Q4 24 | $1.3B | $2.4B | ||
| Q3 24 | $1.3B | $2.4B | ||
| Q2 24 | $920.8M | $2.5B | ||
| Q1 24 | $914.5M | $2.3B |
| Q4 25 | — | 176.99× | ||
| Q3 25 | — | 20.59× | ||
| Q2 25 | — | 8.21× | ||
| Q1 25 | — | 5.79× | ||
| Q4 24 | — | 7.84× | ||
| Q3 24 | — | 4.14× | ||
| Q2 24 | — | 3.94× | ||
| Q1 24 | — | 3.34× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $-2.8M |
| Free Cash FlowOCF − Capex | $29.1M | $-68.6M |
| FCF MarginFCF / Revenue | 11.8% | -47.8% |
| Capex IntensityCapex / Revenue | 0.5% | 45.9% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $-398.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $-2.8M | ||
| Q3 25 | $44.1M | $-24.4M | ||
| Q2 25 | $75.8M | $-5.2M | ||
| Q1 25 | $35.0M | $-85.7M | ||
| Q4 24 | $15.9M | $-8.1M | ||
| Q3 24 | $12.5M | $14.2M | ||
| Q2 24 | $17.4M | $-17.6M | ||
| Q1 24 | $18.3M | $-3.9M |
| Q4 25 | $29.1M | $-68.6M | ||
| Q3 25 | $38.0M | $-90.7M | ||
| Q2 25 | $71.8M | $-87.5M | ||
| Q1 25 | $32.5M | $-151.7M | ||
| Q4 24 | $13.5M | $-34.3M | ||
| Q3 24 | $7.7M | $-11.7M | ||
| Q2 24 | $13.0M | $-32.1M | ||
| Q1 24 | $13.7M | $-16.7M |
| Q4 25 | 11.8% | -47.8% | ||
| Q3 25 | 16.7% | -64.5% | ||
| Q2 25 | 34.0% | -71.6% | ||
| Q1 25 | 16.5% | -157.7% | ||
| Q4 24 | 7.1% | -42.4% | ||
| Q3 24 | 5.2% | -14.0% | ||
| Q2 24 | 9.4% | -37.9% | ||
| Q1 24 | 10.0% | -20.3% |
| Q4 25 | 0.5% | 45.9% | ||
| Q3 25 | 2.7% | 47.2% | ||
| Q2 25 | 1.9% | 67.3% | ||
| Q1 25 | 1.3% | 68.6% | ||
| Q4 24 | 1.3% | 32.5% | ||
| Q3 24 | 3.2% | 31.1% | ||
| Q2 24 | 3.2% | 17.2% | ||
| Q1 24 | 3.3% | 15.6% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | -0.71× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
FIP
| Power Revenues | $45.9M | 32% |
| Rail Revenue | $44.6M | 31% |
| Service Other | $22.8M | 16% |
| Gas Revenues | $15.3M | 11% |
| Roadside Services Revenues | $11.5M | 8% |
| Rapauno | $1.2M | 1% |
